Wide variability in addiction medicine training and treatment have prevented far too many Americans from accessing evidence-based care for this chronic, treatable disease

Standardize It: Delivery of Care

Standardize adm care

ASAM advocates for the use of nationally recognized guidelines and standards for the treatment of addiction and the dissemination of competency-based addiction education for all healthcare professionals.

Advocacy Action

National Initiatives

Modernizing 42 CFR Part 2

ASAM works to reform 42 CFR Part 2 to ensure that patient privacy is protected and clinicians are not subject onerous administrative burdens that delay or prevent the delivery of care. 

 

MATE Act of 2019

H.R. 4974, the MATE Act of 2019, would require all DEA controlled medication prescribers to receive one-time training on treating and managing patients with addiction, unless such a prescriber is otherwise qualified.  It would allow accredited medical schools and residency programs, physician assistant schools, and schools of advanced practice nursing to fulfill the training requirement through comprehensive curriculum that meets the standards laid out in statute, without having to coordinate the development of such education with an outside medical society or state licensing body. This would help normalize addiction medicine education across professional schools and phase out the need for these future practitioners to take a separate, federally mandated addiction training course.  Finally, the training would satisfy the DATA 2000 X-waiver training requirement to prescribe addiction medications, likebuprenorphine, as long as a separate DATA 2000 X-waiver is required by law.

Click here to read a Statement by Leading Addiction Stakeholders 

 

H.R. 6 - SUPPORT for Patients and Communities Act

The SUPPORT for Patients and Communities Act was signed into law on October 24, 2018. The bill contains many provisions designed to standardize the delivery of addiction treatment. You can read a section by section summary of the bill here

  • Directs SAMHSA to provide information for entities applying for grants or cooperative agreements from SAMHSA to encourage the implementation & replication of evidence-based practices
  • Authorizes new grant resources ($10M for each of FY 2019 - 2023) for hospitals and other entities to develop protocols on discharging patients who have presented with an opioid overdose. Protocols would address the provision of an overdose reversal medication, such as naloxone, upon discharge, connection with peer-support specialists, and the referral to treatment and other services that best fit the patient’s needs
  • Oct. 1, 2019 - Sept. 30, 2023: State Medicaid plan amendment option to cover inpatient/residential treatment in facilities with more than 16 beds
    • 30 days for 12 month period
    • Must cover certain ASAM Levels of Care
    • Must ensure eligible individuals receive evidence-based assessments
    • Eligible facilities must follow evidence-based practices and offer at least 2 forms of MAT onsite, including in the case of MAT for OUD, at least one antagonist and one partial agonist
    • On November 6, 2019, CMS issued a State Medicaid Director Letter Regarding Implementation of Section 5052 of the SUPPORT for Patients and Communities Act – State Plan Option under Section 1915(l) of the Social Security Act. 

Subscribe to the ASAM Advocate

Your source for timely, useful news briefings of top stories in addiction policy.